Search Results for “brca” | Page 9

Racial Disparities in Ovarian Cancer Video

Racial Disparities in Ovarian Cancer are Real

Dr. Dineo Khabele, Professor and Chair of the Department of Obstetrics & Gynecology at Washington University School of Medicine in St. Louis and member of OCRA’s Scientific Advisory Committee, spoke at our 2020 Ovarian Cancer National Conference about the racial disparities in ovarian cancer incidences and outcomes. While there are more documented cases of ovarian cancer in white patients…

OCRA Awards Millions in New Ovarian Cancer Research Grants

Despite the challenges of fundraising during a global pandemic, your generous support allowed us to fund 16 top scientists at 14 esteemed medical centers across the globe. They will investigate important issues across the ovarian cancer landscape in this coming year. These grants enable the brightest minds in cancer research to tackle long-standing issues like ovarian cancer drug resistance…

Liya Ding, PhD

Liya Ding, PhD, is an Instructor in the Department of Cancer Biology at Dana-Farber Cancer Institute and the Department of Medicine at Harvard Medical School. Dr. Ding received her B.E. from Tianjin University of Science & Technology, China and Ph.D. from Fudan University, China. After postdoctoral training in the area of epigenetic regulation of gene expression in cancer initiation and progression at Mayo Clinic…

At Your Own Pace, In Your Own Space: How to Be a Hero in a Pandemic

“I don’t think of myself as a hero,” said Amy Hollub, ovarian cancer survivor who—along with the help of her family, close friends, and an advisory board—spearheaded a fundraising event in Miami. “It’s my whole community.” Amy and her husband getting ready to run Indeed, the idea of community plays a big role in Amy’s ovarian cancer experience – from her own family history to those in her synagogue who have been touched by women’s cancers…

What’s New in Ovarian Cancer Research and Treatment

A bright spot in 2020 for the ovarian cancer community has been the ongoing developments in research and treatments. Advances continue to be made, as researchers study the effectiveness of PARP inhibitors as maintenance therapy for ovarian cancer, the most effective way to implement immunotherapy agents, the key factors that can affect the success of secondary debulking surgery…

The Overview: October 2020

It’s been an incredibly busy end of summer/beginning of fall here at OCRA with a double header of Ovarian Cancer Awareness Month and our Uniting for Hope Ovarian Cancer National Conference. We’ve learned so much and strengthened our community. Here are just some of the ways: RESEARCH OCRA is thrilled to announce a partnership with Microsoft’s AI for Health initiative to accelerate ovarian cancer research by harnessing the power of data science and artificial intelligence (AI.) We hosted a listening session with the FDA to better understand the impact of Covid-19 on clinical trial participation…

The Overview: July 2020

There’s so much happening at OCRA – from groundbreaking research to advocacy work, patient support to fundraising efforts. Starting this summer, we will share periodic highlights so that you can stay up to date on the latest. Research A pandemic won’t stop us from our mission to cure ovarian cancer. OCRA is now accepting applications for 2021 research grants…

Finding Sparks, Fueling Motivation | Meet a Scientist

Hui Shen, PhD, spoke of a particular moment that helped cement her commitment to ovarian cancer research. She was working on a complicated project that required a new genomics technology to work. So she and her team enlisted help from an expert. “This technologist made it all happen,” Hui explained. “We were jumping up and down with the data and I thanked her…

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

(May 4, 2020) On April 29th, the Food and Drug Administration approved niraparib (Zejula, GlaxoSmithKline) as a first-line maintenance treatment for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means ovarian cancer patients do not need to have experienced a recurrence to receive the drug…

Up close science photo of a droplet hovering over a beaker

SGO 2020 Highlights

(April 17, 2020) The Society of Gynecologic Oncology's Annual Meeting on Women's Cancer brings together women's healthcare professionals from across the globe to discuss the latest findings in gynecologic oncology. This year, the conference is being held virtually, through a series of high-level webinars that are free and open to the public. Click through to register with the "Registration Link for Non-CE" option…

Writing for Her Life | OCRA Heroes

Jane Rubin speaks quickly, with sentences not so much ending but flowing seamlessly into new thoughts and directions. Listening to her talk about her life and her work is like listening to someone try to cram an epic novel into a paragraph. Her interests and hunger for learning know no bounds. Jane, a 20-year breast cancer survivor…

Update to Benefits of Breastfeeding Against Ovarian Cancer

(April 7, 2020) In a study published last week in the oncology Journal of the American Medical Association, breastfeeding was found to be a factor for reduced risk of developing invasive ovarian cancer. Researchers collected information on close to 10,000 women with ovarian cancer, and found that breastfeeding was associated with a "24% lower risk of invasive ovarian cancer." As stated in the abstract…

For Patients

Research

Advocacy

How to Help

Search Results for brca